Proteasome inhibitors: all 957 studies that test it

Page 5 of 10. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.

• Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT00378105Phase 1/2Results posted
• S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT00376961Phase 2Results posted
• Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular LymphomaTerminatedNCT00372905Phase 1/2Results posted
• Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHLCompletedNCT00369707Phase 2Results posted
• Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell TransplantationCompletedNCT00369226Phase 1/2Results posted
• Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple MyelomaTerminatedNCT00366106Phase 2Results posted
• Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung CancerCompletedNCT00362882Phase 2Results posted
• Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT00312845Phase 3Results posted
• Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell LymphomaCompletedNCT00310037Phase 2Results posted
• Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell TransplantsCompletedNCT00307086Phase 2Results posted
• Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-AmyloidosisCompletedNCT00298766Phase 1/2Results posted
• Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's LymphomaCompletedNCT00295932Phase 1/2Results posted
• A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's LymphomaTerminatedNCT00290706Phase 1/2Results posted
• Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple MyelomaCompletedNCT00287872Phase 2Results posted
• Bortezomib in Treating Patients With Metastatic Kidney CancerCompletedNCT00276614Phase 2Results posted
• Bortezomib in Treating Patients With Myelodysplastic SyndromesCompletedNCT00262873Phase 2Results posted
• Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00262860Phase 2Results posted
• MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous TransplantationTerminatedNCT00256776Phase 3Results posted
• Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms MacroglobulinemiaCompletedNCT00250926Phase 2Results posted
• Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's LymphomaCompletedNCT00201877Phase 2Results posted
• Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate CancerTerminatedNCT00183937Phase 2Results posted
• Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaCompletedNCT00182637Phase 2Results posted
• Bortezomib (Velcade) in Patients With Untreated Multiple MyelomaCompletedNCT00153920Phase 2Results posted
• Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHLCompletedNCT00151320Phase 1/2Results posted
• Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological MalignanciesCompletedNCT00150462Phase 1Results posted
• Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple MyelomaCompletedNCT00148317Phase 2Results posted
• Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00128921Phase 2Results posted
• S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00124579Phase 2Results posted
• Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung CancerCompletedNCT00118144Phase 2Results posted
• EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell LymphomaCompletedNCT00114738Phase 2Results posted
• Tamoxifen and Bortezomib to Treat Recurrent Brain TumorsCompletedNCT00108069Phase 2Results posted
• Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine TherapyCompletedNCT00104871Phase 2Results posted
• Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate CancerTerminatedNCT00103376Phase 2Results posted
• Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT00103259Phase 2Results posted
• Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung CancerCompletedNCT00093756Phase 1/2Results posted
• Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or GallbladderTerminatedNCT00085410Phase 2Results posted
• Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple MyelomaCompletedNCT00084747Phase 1/2Results posted
• Doxorubicin and Bortezomib in Treating Patients With Liver CancerCompletedNCT00083226Phase 2Results posted
• Bortezomib in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00075881Phase 2Results posted
• Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or StomachCompletedNCT00061932Phase 2Results posted
• PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's LymphomaCompletedNCT00054665Phase 2Results posted
• Bortezomib in Treating Patients With Lymphoproliferative DisordersCompletedNCT00023764Phase 2Results posted
• Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00023712Phase 2Results posted
• Feasibility of Using Bortezomib with or Without Chemotherapy in Patients with Atypical Teratoid/rhabdoid TumorsActive, not recruitingNCT06853080Phase 2
• A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06577025Phase 2
• A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT06356571Phase 2
• Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06353022Phase 2
• Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell TransplantationWithdrawnNCT06348147Phase 2
• An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid ArthritisActive, not recruitingNCT06215638Not applicable
• Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Phase 3
• Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN DeletionActive, not recruitingNCT06029998Phase 2
• Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for HypophosphatasiaWithdrawnNCT06015750Phase 4
• SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary DiseaseCompletedNCT05900882Phase 2
• High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHDWithdrawnNCT05895201Phase 1/2
• Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT05804032Phase 3
• A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT05704049Phase 2
• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Phase 3
• Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL StudyActive, not recruitingNCT05392946Phase 1/2
• Bortezomib for Treating Glomerular DiseasesStatus unknownNCT05383547Not applicable
• Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced CancersActive, not recruitingNCT05333276Phase 1
• Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic DisordersWithdrawnNCT05293509Phase 2
• Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple MyelomaSuspendedNCT05199311Phase 1/2
• A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal ImpairmentStatus unknownNCT05147493Phase 2
• Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRDStatus unknownNCT05137860Phase 4
• Isa-RVD Study in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT05123131Phase 2
• A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Phase 3
• Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MMStatus unknownNCT05052970Phase 1
• Marizomib Central Nervous System (CNS)WithdrawnNCT05050305Phase 2
• Carfilzomib and Belatacept for DesensitizationActive, not recruitingNCT05017545Phase 1/2
• Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple MyelomaTerminatedNCT04956302Phase 1
• Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple MyelomaActive, not recruitingNCT04933539Phase 2
• A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial TherapyActive, not recruitingNCT04923893Phase 3
• Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY DiseaseTerminatedNCT04912427Phase 1
• Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04883242Phase 2
• Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04850599Phase 2
• Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain AmyloidosisActive, not recruitingNCT04847453Phase 1
• Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma CellsCompletedNCT04813653Phase 1
• Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe HemoglobinopathiesWithdrawnNCT04776850Early Phase 1
• DARA RVD For High Risk SMMActive, not recruitingNCT04775550Phase 2
• Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).Active, not recruitingNCT04751877Phase 3
• Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM PatientsActive, not recruitingNCT04717700Phase 2
• Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMMActive, not recruitingNCT04653246Phase 2
• Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain AmyloidosisStatus unknownNCT04474938Phase 2
• Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's MacroglobulinemiaCompletedNCT04463953Phase 2
• VR-CAP in the First-line Treatment for Patients With Marginal Zone LymphomaCompletedNCT04433156Phase 2
• Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma PatientsWithdrawnNCT04348006Phase 4
• Phase I Study of Marizomib + Panobinostat for Children With DIPGTerminatedNCT04341311Phase 1
• Trial of Ixazomib for Kaposi SarcomaActive, not recruitingNCT04305691Phase 2
• Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04287855Phase 2
• Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT04285268Phase 2
• Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT04277845Phase 2
• A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 CapsuleStatus unknownNCT04275583Phase 1
• A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple MyelomaActive, not recruitingNCT04268498Phase 2
• A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home EnvironmentTerminatedNCT04268199Phase 2
• Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's MacroglobulinemiaActive, not recruitingNCT04263480Phase 2
• CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in ChildrenCompletedNCT04224571Phase 2
• Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM PatientsCompletedNCT04217967Phase 4
• Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MMActive, not recruitingNCT04176718Phase 2
• TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With BortezomibCompletedNCT04173585Phase 2
• Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary DiseaseActive, not recruitingNCT04166565Phase 2

← Proteasome inhibitors overview